Associations - TMB-H - LARVOL VERI

TMB-H TMB-H	Biliary Tract Cancer Biliary Tract Cancer	TMB-H TMB-H	Biliary Tract Cancer Biliary Tract Cancer	Immunotherapy Sensitive: C3 – Early Trials JCO Precis Oncol - 4 days (New C3)	Immunotherapy Sensitive: C3 – Early Trials JCO Precis Oncol - 4 days - (New C3)
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials Lung Cancer - 2 weeks (New B)	Immunotherapy Sensitive: B - Late Trials Lung Cancer - 2 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline Sci Rep - 3 weeks (New A2)	nivolumab + ipilimumab Sensitive: A2 - Guideline Sci Rep - 3 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	ipilimumab Sensitive: B - Late Trials Sci Rep - 3 weeks (New B)	ipilimumab Sensitive: B - Late Trials Sci Rep - 3 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	nivolumab Sensitive: B - Late Trials Sci Rep - 3 weeks (New B)	nivolumab Sensitive: B - Late Trials Sci Rep - 3 weeks - (New C3)
TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	durvalumab Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks (New C3)	durvalumab Sensitive: C3 – Early Trials Clin Cancer Res - 3 weeks - (New C3)
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	pembrolizumab + ipilimumab Sensitive: C3 – Early Trials Sci Rep - 3 weeks (New C3)	pembrolizumab + ipilimumab Sensitive: C3 – Early Trials Sci Rep - 3 weeks - (New C3)
TMB-H TMB-H	Solid Tumor Solid Tumor	TMB-H TMB-H	Solid Tumor Solid Tumor	pembrolizumab Sensitive: A1 - Approval	pembrolizumab Sensitive: A1 - Approval
TMB-H TMB-H	Peritoneal Cancer Peritoneal Cancer	TMB-H TMB-H	Peritoneal Cancer Peritoneal Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Gastric Cancer Gastric Cancer	TMB-H TMB-H	Gastric Cancer Gastric Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Testicular Seminoma Testicular Seminoma	TMB-H TMB-H	Testicular Seminoma Testicular Seminoma	TIP Sensitive: A2 - Guideline	TIP Sensitive: A2 - Guideline
TMB-H TMB-H	Sarcoma Sarcoma	TMB-H TMB-H	Sarcoma Sarcoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	TMB-H TMB-H	Thyroid Gland Hurthle Cell Carcinoma Thyroid Gland Hurthle Cell Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Chordoma Chordoma	TMB-H TMB-H	Chordoma Chordoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Germ Cell Tumors Germ Cell Tumors	TMB-H TMB-H	Germ Cell Tumors Germ Cell Tumors	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Follicular Carcinoma Thyroid Gland Follicular Carcinoma	TMB-H TMB-H	Thyroid Gland Follicular Carcinoma Thyroid Gland Follicular Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	TMB-H TMB-H	Thyroid Gland Medullary Carcinoma Thyroid Gland Medullary Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Endometrial Cancer Endometrial Cancer	TMB-H TMB-H	Endometrial Cancer Endometrial Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Cervical Cancer Cervical Cancer	TMB-H TMB-H	Cervical Cancer Cervical Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	TMB-H TMB-H	Thyroid Gland Papillary Carcinoma Thyroid Gland Papillary Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab + ipilimumab Sensitive: A2 - Guideline	nivolumab + ipilimumab Sensitive: A2 - Guideline
TMB-H TMB-H	Breast Cancer Breast Cancer	TMB-H TMB-H	Breast Cancer Breast Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Ewing Sarcoma Ewing Sarcoma	TMB-H TMB-H	Ewing Sarcoma Ewing Sarcoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Osteosarcoma Osteosarcoma	TMB-H TMB-H	Osteosarcoma Osteosarcoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Penile Cancer Penile Cancer	TMB-H TMB-H	Penile Cancer Penile Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	TMB-H TMB-H	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	TMB-H TMB-H	Gastroesophageal Junction Adenocarcinoma Gastroesophageal Junction Adenocarcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Esophageal Cancer Esophageal Cancer	TMB-H TMB-H	Esophageal Cancer Esophageal Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Ovarian Cancer Ovarian Cancer	TMB-H TMB-H	Ovarian Cancer Ovarian Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Fallopian Tube Cancer Fallopian Tube Cancer	TMB-H TMB-H	Fallopian Tube Cancer Fallopian Tube Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Neuroendocrine Tumor Neuroendocrine Tumor	TMB-H TMB-H	Neuroendocrine Tumor Neuroendocrine Tumor	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Testicular Cancer Testicular Cancer	TMB-H TMB-H	Testicular Cancer Testicular Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Vulvar Cancer Vulvar Cancer	TMB-H TMB-H	Vulvar Cancer Vulvar Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Prostate Cancer Prostate Cancer	TMB-H TMB-H	Prostate Cancer Prostate Cancer	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma	TMB-H TMB-H	Nasopharyngeal Carcinoma Nasopharyngeal Carcinoma	pembrolizumab Sensitive: A2 - Guideline	pembrolizumab Sensitive: A2 - Guideline
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	atezolizumab Sensitive: B - Late Trials	atezolizumab Sensitive: B - Late Trials
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	atezolizumab + cobimetinib Sensitive: B - Late Trials	atezolizumab + cobimetinib Sensitive: B - Late Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials	vemurafenib + atezolizumab + cobimetinib Sensitive: B - Late Trials
TMB-H TMB-H	Solid Tumor Solid Tumor	TMB-H TMB-H	Solid Tumor Solid Tumor	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
TMB-H TMB-H	Pancreatic Cancer Pancreatic Cancer	TMB-H TMB-H	Pancreatic Cancer Pancreatic Cancer	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab Sensitive: B - Late Trials	durvalumab Sensitive: B - Late Trials
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	pembrolizumab Sensitive: B - Late Trials	pembrolizumab Sensitive: B - Late Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
TMB-H TMB-H	Small Cell Lung Cancer Small Cell Lung Cancer	TMB-H TMB-H	Small Cell Lung Cancer Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: B - Late Trials	nivolumab + ipilimumab Sensitive: B - Late Trials
TMB-H TMB-H	Small Cell Lung Cancer Small Cell Lung Cancer	TMB-H TMB-H	Small Cell Lung Cancer Small Cell Lung Cancer	nivolumab Sensitive: B - Late Trials	nivolumab Sensitive: B - Late Trials
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	PD1 inhibitor Sensitive: B - Late Trials	PD1 inhibitor Sensitive: B - Late Trials
TMB-H TMB-H	Pancreatic Cancer Pancreatic Cancer	TMB-H TMB-H	Pancreatic Cancer Pancreatic Cancer	PD1 inhibitor Sensitive: B - Late Trials	PD1 inhibitor Sensitive: B - Late Trials
TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Squamous Cell Skin Cancer Squamous Cell Skin Cancer	TMB-H TMB-H	Squamous Cell Skin Cancer Squamous Cell Skin Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Colorectal Cancer CRC	TMB-H TMB-H	Colorectal Cancer CRC	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Bladder Cancer Bladder Cancer	TMB-H TMB-H	Bladder Cancer Bladder Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	TMB-H TMB-H	Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	pembrolizumab Sensitive: C1 - Off-label	pembrolizumab Sensitive: C1 - Off-label
TMB-H TMB-H	Gastric Cancer Gastric Cancer	TMB-H TMB-H	Gastric Cancer Gastric Cancer	toripalimab Sensitive: C2 – Inclusion Criteria	toripalimab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Prostate Cancer Prostate Cancer	TMB-H TMB-H	Prostate Cancer Prostate Cancer	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Prostate Cancer Prostate Cancer	TMB-H TMB-H	Prostate Cancer Prostate Cancer	nivolumab Sensitive: C2 – Inclusion Criteria	nivolumab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Solid Tumor Solid Tumor	TMB-H TMB-H	Solid Tumor Solid Tumor	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria	nivolumab + ipilimumab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Solid Tumor Solid Tumor	TMB-H TMB-H	Solid Tumor Solid Tumor	atezolizumab Sensitive: C2 – Inclusion Criteria	atezolizumab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Gastric Cancer Gastric Cancer	TMB-H TMB-H	Gastric Cancer Gastric Cancer	sintilimab Sensitive: C2 – Inclusion Criteria	sintilimab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	sintilimab Sensitive: C2 – Inclusion Criteria	sintilimab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Solid Tumor Solid Tumor	TMB-H TMB-H	Solid Tumor Solid Tumor	sintilimab Sensitive: C2 – Inclusion Criteria	sintilimab Sensitive: C2 – Inclusion Criteria
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	atezolizumab Sensitive: C3 – Early Trials	atezolizumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Neuroendocrine Tumor Neuroendocrine Tumor	TMB-H TMB-H	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials	toripalimab Sensitive: C3 – Early Trials
TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	TMB-H TMB-H	Triple Negative Breast Cancer Triple Negative Breast Cancer	atezolizumab Sensitive: C3 – Early Trials	atezolizumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	CTLA4 inhibitor Sensitive: C3 – Early Trials	CTLA4 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	TMB-H TMB-H	Squamous Cell Carcinoma of Head and Neck SCCHN	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Myelodysplastic Syndrome MDS	TMB-H TMB-H	Myelodysplastic Syndrome MDS	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Prostate Cancer Prostate Cancer	TMB-H TMB-H	Prostate Cancer Prostate Cancer	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Colorectal Cancer CRC	TMB-H TMB-H	Colorectal Cancer CRC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Prostate Cancer Prostate Cancer	TMB-H TMB-H	Prostate Cancer Prostate Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Basal Cell Carcinoma BCC	TMB-H TMB-H	Basal Cell Carcinoma BCC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Glioblastoma GBM	TMB-H TMB-H	Glioblastoma GBM	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Bladder Cancer Bladder Cancer	TMB-H TMB-H	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Breast Cancer Breast Cancer	TMB-H TMB-H	Breast Cancer Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
TMB-H TMB-H	Endometrial Cancer Endometrial Cancer	TMB-H TMB-H	Endometrial Cancer Endometrial Cancer	AB122 Sensitive: C3 – Early Trials	AB122 Sensitive: C3 – Early Trials
TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	TMB-H TMB-H	Non Small Cell Lung Cancer NSCLC	PF-06801591 Sensitive: C3 – Early Trials	PF-06801591 Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	durvalumab + ABSK091 Sensitive: C3 – Early Trials	durvalumab + ABSK091 Sensitive: C3 – Early Trials
TMB-H TMB-H	Melanoma Melanoma	TMB-H TMB-H	Melanoma Melanoma	atezolizumab Sensitive: C3 – Early Trials	atezolizumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials	nivolumab + ipilimumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	avelumab Sensitive: C3 – Early Trials	avelumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Esophageal Cancer Esophageal Cancer	TMB-H TMB-H	Esophageal Cancer Esophageal Cancer	camrelizumab Sensitive: C3 – Early Trials	camrelizumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	TMB-H TMB-H	Urothelial Cancer Urothelial Cancer	ABSK091 Sensitive: C3 – Early Trials	ABSK091 Sensitive: C3 – Early Trials
TMB-H TMB-H	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	TMB-H TMB-H	Thyroid Gland Carcinoma Thyroid Gland Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
TMB-H TMB-H	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	TMB-H TMB-H	Thyroid Gland Anaplastic Carcinoma Thyroid Gland Anaplastic Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials
TMB-H TMB-H	Colorectal Cancer CRC	TMB-H TMB-H	Colorectal Cancer CRC	nivolumab Sensitive: C3 – Early Trials	nivolumab Sensitive: C3 – Early Trials
TMB-H TMB-H	Gastric Cancer Gastric Cancer	TMB-H TMB-H	Gastric Cancer Gastric Cancer	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Colorectal Cancer CRC	TMB-H TMB-H	Colorectal Cancer CRC	PD1 inhibitor Sensitive: C3 – Early Trials	PD1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Colorectal Cancer CRC	TMB-H TMB-H	Colorectal Cancer CRC	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials
TMB-H TMB-H	Gastric Cancer Gastric Cancer	TMB-H TMB-H	Gastric Cancer Gastric Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials	PD-L1 inhibitor Sensitive: C3 – Early Trials